{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:06:30Z","timestamp":1780391190231,"version":"3.54.1"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T00:00:00Z","timestamp":1405641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0100159","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T18:37:51Z","timestamp":1405708671000},"page":"e100159","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Nation-Wide Multicenter 10-Year (1999-2008) Retrospective Clinical Study of Endocrine Therapy for Chinese Females with Breast Cancer"],"prefix":"10.1371","volume":"9","author":[{"given":"Can","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin hu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao ming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong hua","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You lin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","article-title":"New strategies in estrogen receptor\u2013positive breast cancer","volume":"16","author":"SR Johnston","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.9-5-507","article-title":"What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?","volume":"9","author":"TM Prowell","year":"2004","journal-title":"Oncologist"},{"key":"ref3","first-page":"595","article-title":"Adrenalectomy for mammary cancer","volume":"136","author":"C Huggins","year":"1952","journal-title":"Annals of Surgery"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/pgmj.34.398.628","article-title":"The surgery of the endocrine system in carcinoma of the breast","volume":"34","author":"J Hadfield","year":"1958","journal-title":"Postgrad Med J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000658-197311000-00001","article-title":"Conversion of hydrocortisone to estrogen in carcinoma of the breast after oophorectomy and adrenalectomy","volume":"178","author":"LS Geary","year":"1973","journal-title":"Annals of Surgery"},{"key":"ref6","first-page":"169","article-title":"Androgens in breast cancer. III. Breast cancer recurrences years after mastectomy and increased androgenic activity","volume":"121","author":"R Grattarola","year":"1975","journal-title":"Am J Obstet Gynecol"},{"key":"ref7","first-page":"22","article-title":"Endocrine therapy - The Future","volume":"67","author":"J Hayward","year":"1974","journal-title":"Proc Roy Soc Med"},{"key":"ref8","first-page":"1317","article-title":"Antiestrogens:a new endocrine treatment possibility in metastasizing breast neoplasms. Experiences of the Swiss Cooperative Cancer Study Group with tamoxifen","volume":"108","author":"WF Jungi","year":"1978","journal-title":"Schweiz Med Wochenschr"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1136\/bmj.1.6075.1534-d","article-title":"Effects of tamoxifen in relation to breast cancer","volume":"1","author":"VC Jordan","year":"1977","journal-title":"Br Med J"},{"key":"ref10","first-page":"3424s","article-title":"Antiestrogen treatment of breast cancer: An overview","volume":"42","author":"OH Pearson","year":"1982","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1983.100","article-title":"Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer","volume":"47","author":"AL Harris","year":"1983","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.21707","article-title":"Landmark trials in endocrine adjuvant therapy for breast carcinoma","volume":"106","author":"Gradishar William","year":"2006","journal-title":"Cancer"},{"key":"ref14","first-page":"2131","article-title":"ATAC Trialists' Group","volume":"359","author":"M Baum","year":"2002","journal-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial.Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/107327480401100402","article-title":"Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial","volume":"11","author":"M Baum","year":"2004","journal-title":"Cancer Control"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"M Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2006.03.026","article-title":"The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG1-98 letrozole trial","volume":"33","author":"JF Forbes","year":"2006","journal-title":"Semin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ctrv.2007.07.014","article-title":"Reducing the risk of distant metastases in breast cancer patients:role of aromatase inhibitors","volume":"33","author":"LD Mastro","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ctrv.2007.11.001","article-title":"Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review","volume":"34","author":"A Eisen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"J Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2011.36.8993","article-title":"Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group","volume":"30","author":"PC Dubsky","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.21707","article-title":"Landmark trials in endocrine adjuvant therapy for breast carcinoma","volume":"106","author":"W Gradishar","year":"2006","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up","volume":"12","author":"MM Regan","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2003.04.576","article-title":"Meeting highlights:updated international expert consensus on the primary therapy of early breast cancer","volume":"21","author":"A Goldhirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2012.00092","article-title":"Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance","volume":"3","author":"K Dickschen","year":"2012","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/JOP.2011.000417","article-title":"Endocrine therapy initiation from 2001 to 2008 varies by age at breast ca-ncer diagnosis and tumor size","volume":"8","author":"EJ Bowles","year":"2012","journal-title":"J Oncol Pract"},{"key":"ref28","first-page":"1","article-title":"A nationwide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China","volume":"11","author":"J Li","year":"2011","journal-title":"BMC Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e87224","DOI":"10.1371\/journal.pone.0087224","article-title":"Body mass index and breast cancer defined by biological receptor status in pre-menopausal and post-menopausal women: a multicenter study in China","volume":"9","author":"J Li","year":"2014","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"JM Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref31","first-page":"601","article-title":"Differences in breast cancer hormone receptor status and histology by rac-e and ethnicity among women 50 years of age and older.Cancer Epidemiol Biomarkers Prev","volume":"11","author":"CI Li","year":"2002"},{"key":"ref32","first-page":"105","article-title":"Use of estrogen receptor data: recommendations for Iowa","volume":"70","author":"MP Corder","year":"1980","journal-title":"J Iowa Med Soc"},{"key":"ref33","first-page":"153","article-title":"Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer","volume":"69","author":"Y Nomura","year":"1992","journal-title":"Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/annonc\/mdl016","article-title":"Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status","volume":"17","author":"M Dowsett","year":"2006","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2008.19.2419","article-title":"Adjuvant hormonal therapy use among insured, low-income women with breast cancer","volume":"27","author":"G Kimmick","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.6004\/jnccn.2009.0011","article-title":"Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer","volume":"7","author":"TH Svahn","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1200\/JCO.2004.11.064","article-title":"Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor\u2013positive breast cancer","volume":"22","author":"AK Fink","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref38","first-page":"872","article-title":"Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987\u20132000.J Clin Onco","volume":"24","author":"LC Harlan","year":"2006"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1445-2197.2006.03846.x","article-title":"National breast cancer audit: overview of invasive breast cancer management","volume":"76","author":"AV Cuncins-Hearn","year":"2006","journal-title":"ANZ J Surg"},{"key":"ref40","first-page":"180574","article-title":"Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal women with hormone receptor-positive early-stage breast cancer","volume":"2012","author":"O Nguyen","year":"2012","journal-title":"Int J Surg Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1023\/A:1008334404825","article-title":"Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors","volume":"11","author":"M Colleoni","year":"2000","journal-title":"Ann Onco"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study","volume":"12","author":"W Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer evidence from a phase III randomized trial","volume":"19","author":"MJ Ellis","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"IE Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.21872","article-title":"Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial","volume":"106","author":"L Cataliotti","year":"2006","journal-title":"Cancer"},{"key":"ref46","first-page":"422","article-title":"Neoadjuvant radiotherapy and hormonotherapy in locally advanced breast cancer: state of the art","volume":"25","author":"M Padilha","year":"2012","journal-title":"Acta Med Port"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"x243","DOI":"10.1093\/annonc\/mds305","article-title":"Neoadjuvant therapy for ER-positive breast cancers","volume":"23","author":"M Colleoni","year":"2012","journal-title":"Ann Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","article-title":"Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer","volume":"110","author":"VF Semiglazov","year":"2007","journal-title":"Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ctrv.2012.06.011","article-title":"A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women","volume":"39","author":"F Cardoso","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.21474","article-title":"Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early stage breast carcinoma patients","volume":"104","author":"M Belfiglio","year":"2005","journal-title":"Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1188\/08.CJON.213-221","article-title":"Adherence to oral endocrine therapy for breast cancer: A nursing perspective","volume":"1","author":"C Miaskowski","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/092986713804999303","article-title":"Treatment of estrogen receptor- positive breast cancer","volume":"20","author":"F Lumachi","year":"2013","journal-title":"Curr Med Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jnci\/95.5.338","article-title":"Is tamoxifen the Rosetta stone for breast cancer?","volume":"95","author":"VC Jordan","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.bjc.6601508","article-title":"First-line endocrine treatment of breast cancer: aromatase inhibitor or antioes-trogen?","volume":"90","author":"ZW Wong","year":"2004","journal-title":"Br J Cancer"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2005.01.4829","article-title":"Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study","volume":"23","author":"M Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of ta-moxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"RC Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/COC.0b013e3182436ec1","article-title":"Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women","volume":"36","author":"KE Weaver","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/jwh.2008.1127","article-title":"The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review","volume":"18","author":"L Vona-Davis","year":"2009","journal-title":"J Womens Health(Larchmt)"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"e82720","DOI":"10.1371\/journal.pone.0082720","article-title":"Health information seeking partially mediated the association between socioeconomic status and self-rated health among Hong Kong Chinese","volume":"8(12)","author":"MP Wang","year":"2013","journal-title":"PLoS One 13"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"KJ Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/0284186X.2011.619567","article-title":"Eligibility,compliance and persistence of extended adjuvant endocrine therapy for breast cancer","volume":"51","author":"ME Myrick","year":"2012","journal-title":"Acta Oncologica"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2009.02.001","article-title":"Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy","volume":"73","author":"P Hadji","year":"2010","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0100159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:36:35Z","timestamp":1565656595000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0100159"}},"subtitle":[],"editor":[{"given":"William B.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,18]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0100159","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,18]]}}}